MedPath

HeartBeam

🇺🇸United States
Ownership
-
Employees
15
Market Cap
-
Website
Introduction

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (100.0%)

AIMIGo 12L ECG Synthesis Software Pivotal Study for Arrythmia Detection

Not Applicable
Completed
Conditions
Arrhythmias, Cardiac
Tachycardia
Atrial Flutter
Bradycardia
Atrial Fibrillation
First Posted Date
2023-11-08
Last Posted Date
2024-07-05
Lead Sponsor
HeartBeam, Inc.
Target Recruit Count
198
Registration Number
NCT06123130
Locations
🇺🇸

Piedmont Heart Institute, Atlanta, Georgia, United States

🇺🇸

Atlanta Heart Specialists, Tucker, Georgia, United States

🇺🇸

The Mount Sinai Hospital, New York, New York, United States

and more 2 locations

News

HeartBeam Submits FDA Application for 12-Lead ECG Synthesis Software

HeartBeam has submitted a 510(k) application to the FDA for its 12-lead ECG synthesis software, designed to assess various cardiac rhythms and arrhythmias.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.